Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
959.41
+43.35 (4.73%)
At close: Nov 11, 2026, 4:00 PM EST
964.90
+5.49 (0.57%)
After-hours: Nov 11, 2026, 7:57 PM EST
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,983 | 13,640 | 13,687 | 12,581 | 11,808 | 15,791 |
Other Revenue | 913.1 | 702.6 | 515 | 536.1 | 365.1 | 281.2 |
| 16,896 | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 | |
Revenue Growth | 18.59% | 0.99% | 8.27% | 7.76% | -24.26% | 89.14% |
Cost of Revenue | 9,000 | 7,951 | 7,103 | 6,255 | 5,153 | 5,298 |
Gross Profit | 7,896 | 6,392 | 7,100 | 6,862 | 7,020 | 10,774 |
Selling, General & Admin | 2,763 | 2,700 | 2,954 | 2,631 | 2,116 | 1,825 |
Other Operating Expenses | - | -10 | - | -2.1 | -89.9 | -45.6 |
Operating Expenses | 2,763 | 2,690 | 2,954 | 2,629 | 2,026 | 1,779 |
Operating Income | 5,134 | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 |
Interest Expense | -46.7 | -43.8 | -55.2 | -73 | -59.4 | -57.3 |
Interest & Investment Income | 741.9 | 716.8 | 711.4 | 495.9 | 160.1 | 45.8 |
Currency Exchange Gain (Loss) | 2.4 | 2.4 | -0.6 | -0.3 | 50.2 | 0.4 |
Other Non Operating Income (Expenses) | 955.7 | 988 | 15.9 | -28.8 | 8.8 | 4 |
EBT Excluding Unusual Items | 6,787 | 5,365 | 4,817 | 4,627 | 5,154 | 8,988 |
Gain (Loss) on Sale of Investments | -831 | -10.6 | 117.7 | -241.6 | -39.8 | 386.1 |
Other Unusual Items | - | - | -53.4 | - | - | - |
Pretax Income | 5,687 | 5,231 | 4,780 | 4,199 | 4,859 | 9,326 |
Income Tax Expense | 869.4 | 725.8 | 367.3 | 245.7 | 520.4 | 1,251 |
Net Income | 4,817 | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
Net Income to Common | 4,817 | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
Net Income Growth | 5.23% | 2.09% | 11.61% | -8.87% | -46.28% | 129.86% |
Shares Outstanding (Basic) | 103 | 105 | 108 | 107 | 107 | 106 |
Shares Outstanding (Diluted) | 107 | 109 | 115 | 114 | 114 | 112 |
Shares Change | -3.11% | -5.65% | 1.23% | 0.18% | 1.16% | -2.52% |
EPS (Basic) | 46.83 | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 |
EPS (Diluted) | 45.17 | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 |
EPS Growth | 8.59% | 8.19% | 10.27% | -9.03% | -46.89% | 135.81% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3,826 | 4,081 | 3,665 | 3,875 | 4,425 | 6,529 |
Free Cash Flow Per Share | 35.88 | 37.57 | 31.84 | 34.08 | 38.98 | 58.19 |
Dividend Per Share | 3.700 | 3.520 | - | - | - | - |
Dividend Growth | 40.15% | - | - | - | - | - |
Gross Margin | 46.73% | 44.57% | 49.99% | 52.32% | 57.67% | 67.04% |
Operating Margin | 30.38% | 25.81% | 29.19% | 32.27% | 41.03% | 55.97% |
Profit Margin | 28.51% | 31.41% | 31.07% | 30.14% | 35.64% | 50.24% |
Free Cash Flow Margin | 22.65% | 28.45% | 25.80% | 29.54% | 36.35% | 40.63% |
EBITDA | 5,647 | 4,246 | 4,628 | 4,654 | 5,335 | 9,281 |
EBITDA Margin | 33.42% | 29.60% | 32.59% | 35.48% | 43.83% | 57.75% |
D&A For EBITDA | 512.9 | 543.7 | 482.9 | 421 | 341.4 | 286.2 |
EBIT | 5,134 | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 |
EBIT Margin | 30.38% | 25.81% | 29.19% | 32.27% | 41.03% | 55.97% |
Effective Tax Rate | 15.29% | 13.88% | 7.68% | 5.85% | 10.71% | 13.41% |
Revenue as Reported | 16,896 | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 |